In today’s briefing:
- Japfa (JAP SP): The Santosa Family (Finally) Makes A Move
- SLB Dev (SLB SP): Ong Family Offer By Way Of A Scheme.
- Bund Center Investment (BTE SP): A Dominant Real Estate Play on the Bund
- Hyphens Pharma (HYP SP): ASEAN’S Leading Specialty Pharma Company
- 10 in 10 with International Cement Group – Tapping growth opportunities in Central Asia
Japfa (JAP SP): The Santosa Family (Finally) Makes A Move
- Back in March of last year, Bloomberg reported,that Renaldo Santosa and his family, who collectively controlled ~75.5% of agri-play Japfa Ltd (JAP SP), were considering taking Japfa private.
- This was discussed in Japfa (JAP SP): Impressive Gain. But No Firm Offer. Then crickets.
- The family has now pitched an Offer of S$0.62/share, by way of a Scheme, a 34.8% premium to undisturbed. That’s probably enough to get this over the line.
SLB Dev (SLB SP): Ong Family Offer By Way Of A Scheme.
- Singaporean property play SLB Development (SLB SP) has announced an Offer, by way of a Scheme, from Lian Beng (LBG SP)‘s Ong family, at S$0.23/share, a 36.1% premium to undisturbed.
- Lian Beng, which was privatised by the Ong family in 2023 – see Lian Beng: Circ Out. IFA (Rightfully) Says Not Fair – holds 77.6% in SLB.
- This is done. No competing offer will emerge. I don’t think this needs a bump.
Bund Center Investment (BTE SP): A Dominant Real Estate Play on the Bund
- Bund Center Investment (BCI) is a diversified investment vehicle with two commercial real estate assets: the landmark Westin Bund Center Hotel, and its premium office space, Bund Center Office Tower in Shanghai.
- BCI operates under two business segments: Hotel Operations and Property Leasing.
- Despite short-term hurdles, long-term economic growth in China provides a supportive backdrop.
Hyphens Pharma (HYP SP): ASEAN’S Leading Specialty Pharma Company
- Hyphens Pharma (HYP SP EQUITY) is Singapore’s leading specialty pharmaceutical and consumer healthcare group, leveraging on its diverse footprints in ASEAN countries. Its core business lies in three segments: Specialty Pharma Principals, Proprietary Brands, and Medical Hypermart and Digital.
- Based on its scalable business model, direct access to the five countries in the southeast Asia region enabling it to capture health expenditure growth in ASEAN countries, sustainable growth from both in-house product innovation and in-licensing cooperation, as well as realization of DocMed’s potential when rolling out the digital platform to other ASEAN markets, Hyphens Pharma will demonstrate sustainable growth momentum and optimistic investment value in the future.
- Revenue in 2024 full year is expected to show a strong rebound compared to 2023.
10 in 10 with International Cement Group – Tapping growth opportunities in Central Asia
- 10 Questions for International Cement Group What are some of your business segments, and how are they performing? International Cement Group’s principal business is in the production and distribution of cement in two major countries in Central Asia – Kazakhstan and Tajikistan – accounting for more than 95% of revenue.
- Why is this a focus market for International Cement Group, and how does the Group navigate potential challenges?.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
